Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Am J Transplant ; 20(11): 3051-3060, 2020 11.
Article in English | MEDLINE | ID: mdl-32654332

ABSTRACT

Solid organ transplant recipients (SOTr) with coronavirus disease 2019 (COVID-19) are expected to have poorer outcomes compared to nontransplant patients because of immunosuppression and comorbidities. The clinical characteristics of 47 SOTr (38 kidneys and 9 nonkidney organs) were compared to 100 consecutive hospitalized nontransplant controls. Twelve of 47 SOTr managed as outpatients were subsequently excluded from the outcome analyses to avoid potential selection bias. Chronic kidney disease (89% vs 57% P = .0007), diabetes (66% vs 33% P = .0007), and hypertension (94% vs 72% P = .006) were more common in the 35 hospitalized SOTr compared to controls. Diarrhea (54% vs 17%, P < .0001) was more frequent in SOTr. Primary composite outcome (escalation to intensive care unit, mechanical ventilation, or in-hospital all-cause mortality) was comparable between SOTr and controls (40% vs 48%, odds ratio [OR] 0.72 confidence interval [CI] [0.33-1.58] P = .42), despite more comorbidities in SOTr. Acute kidney injury requiring renal replacement therapy occurred in 20% of SOTr compared to 4% of controls (OR 6 CI [1.64-22] P = .007). Multivariate analysis demonstrated that increasing age and clinical severity were associated with mortality. Transplant status itself was not associated with mortality.


Subject(s)
COVID-19/epidemiology , Graft Rejection/prevention & control , Immunosuppression Therapy/methods , Organ Transplantation , Pandemics , SARS-CoV-2 , Transplant Recipients , Aged , Comorbidity , Female , Graft Rejection/epidemiology , Humans , Incidence , Intensive Care Units , Male , Middle Aged , Retrospective Studies , Risk Factors , United States/epidemiology
2.
Clin Lymphoma Myeloma Leuk ; 12(1): 66-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22000698

ABSTRACT

BACKGROUND: Guidelines for primary Pneumocystis jirovecii pneumonia (PCP) prophylaxis for patients with hematologic malignancy (HM) are still lacking. Our objective was to identify risk factors for PCP among patients with HM to help recognize patients who would benefit from primary PCP prophylaxis. MATERIAL AND METHODS: We performed a case-control study of adult patients with HM and negative for human immunodeficiency virus and with confirmed PCP by using cytology or histopathology from 2 medical centers over an 11-year period. Each case was matched with 4 patients without PCP by type of HM and year of treatment. We compared demographic, clinical, and laboratory data among cases and controls. Data were analyzed by using SPSS version 18.0. RESULTS: Fourteen cases and 56 controls were included in the study period. No significant differences were seen in demographics between both groups. All identified patients had lymphoproliferative HM, the majority of patients (93%) had either non-Hodgkin lymphoma or chronic lymphocytic leukemia. Autoimmune diseases were more frequent in cases vs. controls (28.6% vs. 5.4% P = .01). The receipt and duration of chemotherapy were similar in both groups. Among chemotherapeutic agents, including steroids, only fludarabine was associated with increased risk for PCP (50% vs. 17.9%; P = .02). No difference was found in total or lymphocyte percentage in cases at the time of PCP diagnosis vs. nadir values in controls. CONCLUSION: Patients with lymphoproliferative HM, specifically chronic lymphocytic leukemia and non-Hodgkin lymphoma, who are receiving fludarabine and with autoimmune disorders are at increased risk for PCP and should be considered for PCP primary prophylaxis.


Subject(s)
Antineoplastic Agents/therapeutic use , Lymphoproliferative Disorders/drug therapy , Pneumocystis carinii/drug effects , Pneumonia, Pneumocystis/prevention & control , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Aged , Aged, 80 and over , Case-Control Studies , Cladribine/therapeutic use , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/drug therapy , Lymphoproliferative Disorders/complications , Male , Middle Aged , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/diagnosis , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use
3.
Ann Transplant ; 15(4): 77-83, 2010.
Article in English | MEDLINE | ID: mdl-21183881

ABSTRACT

BACKGROUND: Whether there are geographic differences in clinical presentation of cryptococcosis in solid organ transplant (SOT) recipients in the United States (US) is not known. MATERIAL/METHODS: Patients comprised a cohort of 120 SOT recipients from US transplant centers who fulfilled the EORTC/MSG criteria for cryptococcal disease. RESULTS: Central nervous system, pulmonary, and cutaneous cryptococcal disease were observed in 51% (61/120), 64% (77/120), and 15% (18/120) of the patients, respectively. Cutaneous disease was documented in 9% (3/32) of the patients from South Atlantic region, 19% (6/32) from Mid Atlantic, 26% (6/23) from Southern, 7% (2/29) from Midwestern, and in 1 of 4 patients from the Northwestern region of the US. When controlled for age, immunosuppressive regimen, type of transplant, and renal failure at baseline, patients from the Southern compared with other regions of the US were significantly more likely to have cutaneous cryptococcal disease (OR 3.8, 95% CI 1.1-14, P=0.045). CONCLUSIONS: Post-transplant cryptococcosis is more likely to present with cutaneous disease in the Southern region compared with other regions in the US. This predilection for cutaneous cryptococcosis could not be explained on the basis of differences in immunosuppression or the type of transplant. Whether our findings are related to strain-related variations in characteristics of the yeast or other transplant variables remains to be determined.


Subject(s)
Cryptococcosis/diagnosis , Dermatomycoses/diagnosis , Organ Transplantation/adverse effects , Climate , Cohort Studies , Female , Hot Temperature , Humans , Male , Middle Aged , United States
4.
Clin Infect Dis ; 51(9): 1062-9, 2010 Nov 01.
Article in English | MEDLINE | ID: mdl-20879857

ABSTRACT

BACKGROUND: Cryptococcosis occurring ≤30 days after transplantation is an unusual event, and its characteristics are not known. METHODS: Patients included 175 solid-organ transplant (SOT) recipients with cryptococcosis in a multicenter cohort. Very early-onset and late-onset cryptococcosis were defined as disease occurring ≤30 days or >30 days after transplantation, respectively. RESULTS: Very early-onset disease developed in 9 (5%) of the 175 patients at a mean of 5.7 days after transplantation. Overall, 55.6% (5 of 9) of the patients with very early-onset disease versus 25.9% (43 of 166) of the patients with late-onset disease were liver transplant recipients (P = .05). Very early cases were more likely to present with disease at unusual locations, including transplanted allograft and surgical fossa/site infections (55.6% vs 7.2%; P < .001). Two very early cases with onset on day 1 after transplantation (in a liver transplant recipient with Cryptococcus isolated from the lung and a heart transplant recipient with fungemia) likely were the result of undetected pretransplant disease. An additional 5 cases involving the allograft or surgical sites were likely the result of donor‐acquired infection. CONCLUSIONS: A subset of SOT recipients with cryptococcosis present very early after transplantation with disease that appears to occur preferentially in liver transplant recipients and involves unusual sites, such as the transplanted organ or the surgical site. These patients may have unrecognized pretransplant or donor-derived cryptococcosis.


Subject(s)
Cryptococcosis/diagnosis , Cryptococcosis/transmission , Cryptococcus/isolation & purification , Postoperative Complications/diagnosis , Tissue Donors , Transplants/adverse effects , Adult , Aged , Cohort Studies , Cryptococcosis/epidemiology , Cryptococcosis/microbiology , Female , Humans , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/microbiology , Time Factors
5.
Transplantation ; 89(1): 69-74, 2010 Jan 15.
Article in English | MEDLINE | ID: mdl-20061921

ABSTRACT

BACKGROUND: Cerebrospinal fluid (CSF) analysis is often deferred in patients with cryptococcal disease, particularly in the absence of neurologic manifestations. We sought to determine whether a subset of solid organ transplant (SOT) recipients with high likelihood of central nervous system (CNS) disease could be identified in whom CSF analysis must be performed. METHODS: Patients comprised a multicenter cohort of SOT recipients with cryptococcosis. RESULTS: Of 129 (88%) of 146 SOT recipients with cryptococcosis who underwent CSF analysis, 80 (62%) had CNS disease. In the overall study population, abnormal mental status, time to onset of cryptococcosis more than 24 months posttransplantation (late-onset disease), serum cryptococcal antigen titer more than 1:64, and fungemia were independently associated with an increased risk of CNS disease. Of patients with abnormal mental status, 95% had CNS cryptococcosis. When only patients with normal mental status were considered, three predictors (serum antigen titer >1:64, fungemia, and late-onset disease) independently identified patients with CNS cryptococcosis; the risk of CNS disease was 14% if none, 39% if one, and 94% if two of the aforementioned predictors existed (chi for trend P<0.001). CONCLUSIONS: CSF analysis should be strongly considered in SOT recipients with cryptococcosis who have late-onset disease, fungemia, or serum cryptococcal antigen titer more than 1:64 even in the presence of normal mental status.


Subject(s)
Central Nervous System Diseases/epidemiology , Cryptococcosis/epidemiology , Organ Transplantation/adverse effects , Adult , Antigens, Fungal/blood , Chi-Square Distribution , Cohort Studies , Cryptococcosis/complications , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/therapeutic use , Likelihood Functions , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/microbiology , Predictive Value of Tests , Prospective Studies , Regression Analysis
6.
Med Mycol ; 48(6): 785-91, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20100136

ABSTRACT

Clinical manifestations, treatment, and outcomes of cutaneous cryptococcosis in solid organ transplant (SOT) recipients are not fully defined. In a prospective cohort comprising 146 SOT recipients with cryptococcosis, we describe the presentation, antifungal therapy, and outcome of cutaneous cryptococcal disease. Cutaneous cryptococcosis was documented in 26/146 (17.8%) of the patients and manifested as nodular/mass (34.8%), maculopapule (30.4%), ulcer/pustule/abscess (30.4%), and cellulitis (30.4%) with 65.2% of the skin lesions occurred in the lower extremities. Localized disease developed in 30.8% (8/26), and disseminated disease in 69.2% (18/26) with involvement of the central nervous system (88.9%, 16/18), lung (33.3%, 6/18), or fungemia (55.6%, 10/18). Fluconazole (37.5%) was employed most often for localized and lipid formulations of amphotericin B (61.1%) for disseminated disease. Overall mortality at 90 days was 15.4% (4/26) with 16.7% in disseminated and 12.5% in localized disease (P = 0.78). SOT recipients who died were more likely to have renal failure (75.0% vs. 13.6%, P = 0.028), longer time to onset of disease after transplantation (87.5 vs. 22.6 months, P = 0.023), and abnormal mental status (75% vs. 13.6%, P = 0.028) than those who survived. Cutaneous cryptococcosis represents disseminated disease in most SOT recipients and preferentially involves the extremities. Outcomes with appropriate management were comparable between SOT recipients with localized and disseminated cryptococcosis.


Subject(s)
Cryptococcosis/pathology , Cryptococcus neoformans/isolation & purification , Dermatomycoses/pathology , Transplants/adverse effects , Antifungal Agents/therapeutic use , Central Nervous System Fungal Infections/epidemiology , Central Nervous System Fungal Infections/mortality , Cohort Studies , Cryptococcosis/complications , Cryptococcosis/drug therapy , Cryptococcosis/mortality , Dermatomycoses/complications , Dermatomycoses/drug therapy , Dermatomycoses/mortality , Female , Fluconazole/therapeutic use , Fungemia/epidemiology , Fungemia/mortality , Humans , Lung Diseases, Fungal/epidemiology , Lung Diseases, Fungal/mortality , Male , Middle Aged , Prospective Studies , Transplantation
7.
Clin Infect Dis ; 49(11): 1721-8, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19886800

ABSTRACT

BACKGROUND: Whether outcome of central nervous system (CNS) cryptococcosis in solid organ transplant recipients treated with lipid formulations of amphotericin B is different from the outcome of the condition treated with amphotericin B deoxycholate (AmBd) is not known. METHODS: We performed a multicenter study involving a cohort comprising consecutive solid organ transplant recipients with CNS cryptococcosis. RESULTS: Of 75 patients treated with polyenes as induction regimens, 55 (73.3%) received lipid formulations of amphotericin B and 20 (26.7%) received AmBd. Similar proportions of patients in both groups had renal failure at baseline (P = .94 ). Overall, mortality at 90 days was 10.9% in the group that received lipid formulations of amphotericin B and 40.0% in the group that received AmBd. In univariate analysis, nonreceipt of calcineurin inhibitors (P = .034), renal failure at baseline (P = .016), and fungemia (P = .003) were significantly associated with mortality. Compared with AmBd, lipid formulations of amphotericin B were associated with a lower mortality (P = .007). Mortality did not differ between patients receiving lipid formulations of amphotericin B with or without flucytosine (P = .349). In stepwise logistic regression analysis, renal failure at baseline (odds ratio [OR], 4.61; 95% confidence interval [CI], 1.02-20.80; P = .047) and fungemia (OR, 10.66; 95% CI, 2.08-54.55; P = .004 ) were associated with an increased mortality, whereas lipid formulations of amphotericin B were associated with a lower mortality (OR, 0.11; 95% CI, 0.02-0.57; P = .008). CONCLUSIONS: Lipid formulations of amphotericin B were independently associated with better outcome and may be considered as the first-line treatment for CNS cryptococcosis in these patients.


Subject(s)
Amphotericin B/chemistry , Amphotericin B/therapeutic use , Antifungal Agents , Central Nervous System Diseases , Cryptococcosis/drug therapy , Lipids/chemistry , Transplants , Adult , Antifungal Agents/chemistry , Antifungal Agents/therapeutic use , Central Nervous System Diseases/drug therapy , Central Nervous System Diseases/microbiology , Drug Compounding , Female , Humans , Male , Middle Aged , Prospective Studies , Treatment Outcome
8.
Transplantation ; 86(5): 647-51, 2008 Sep 15.
Article in English | MEDLINE | ID: mdl-18791444

ABSTRACT

BACKGROUND: Prognostic implications of cryptococcal antigen and outcomes associated with central nervous system (CNS) cryptococcal lesions in solid organ transplant recipients have not been fully defined. METHODS: Patients were derived form a cohort of 122 solid organ transplant recipients with cryptococcosis in a multicenter study from 1999 to 2006. RESULTS: Central nervous system cryptococcosis was documented in 61 patients. Serum or cerebral spinal fluid antigen titers did not correlate with mortality at 90 days or cerebral spinal fluid sterilization at 2 weeks. Central nervous system lesions were identified in 16 patients and included leptomeningeal lesions in eight, parenchymal lesions in six, and hydrocephalus in two. Overall, 13/16 CNS lesions were present at the time of diagnosis. One parenchymal and two hydrocephalus lesions, however, developed after diagnosis and fulfilled the criteria for immune reconstitution syndrome. Cerebral spinal fluid antigen titers were higher with meningeal versus parenchymal lesions, and hydrocephalus (P=0.015). Mortality was 50% (3/6) for patients with parenchymal, 12.5% (1/8) for those with leptomeningeal, and 0/3 for patients with hydrocephalus. Mortality was 31% (4/13) for patients with CNS lesions at baseline and 0/3 in those with new onset lesions. CONCLUSIONS: Despite a higher antigen titer with meningeal lesions, outcomes tended to be worse with parenchymal compared with meningeal lesions or hydrocephalus. New onset CNS lesions may represent immune reconstitution syndrome and seemed to be associated with better outcome.


Subject(s)
Meningitis, Cryptococcal/epidemiology , Organ Transplantation/adverse effects , Postoperative Complications/microbiology , Adult , Aged , Cerebrospinal Fluid/microbiology , Cryptococcus/isolation & purification , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies
9.
Clin Infect Dis ; 46(2): e12-8, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-18171241

ABSTRACT

BACKGROUND: The role of serum cryptococcal antigen in the diagnosis and determinants of antigen positivity in solid organ transplant (SOT) recipients with pulmonary cryptococcosis has not been fully defined. METHODS: We conducted a prospective, multicenter study of SOT recipients with pulmonary cryptococcosis during 1999-2006. RESULTS: Forty (83%) of 48 patients with pulmonary cryptococcosis tested positive for cryptococcal antigen. Patients with concomitant extrapulmonary disease were more likely to have a positive antigen test result (P=.018), and antigen titers were higher in patients with extrapulmonary disease (P=.003) or fungemia (P=.045). Patients with single nodules were less likely to have a positive antigen test result than were those with all other radiographic presentations (P=.053). Among patients with isolated pulmonary cryptococcosis, lung transplant recipients were less likely to have positive cryptococcal antigen test results than were recipients of other types of SOT (P=.003). In all, 38% of the patients were asymptomatic or had pulmonary cryptococcosis detected as an incidental finding. Nodular densities or mass lesions were more likely to present as asymptomatic or incidentally detected pulmonary cryptococcosis than as pleural effusions and infiltrates (P=.008). CONCLUSIONS: A positive serum cryptococcal antigen test result in SOT recipients with pulmonary cryptococcosis appears to reflect extrapulmonary or more advanced radiographic disease.


Subject(s)
Antigens, Fungal/blood , Cryptococcosis/immunology , Cryptococcus neoformans/immunology , Lung Diseases, Fungal/immunology , Transplantation Immunology , Adult , Aged , Cohort Studies , Cryptococcosis/blood , Cryptococcosis/microbiology , Cryptococcus neoformans/isolation & purification , Female , Fungemia/immunology , Fungemia/microbiology , Humans , Immunocompromised Host , Lung Diseases, Fungal/blood , Lung Diseases, Fungal/microbiology , Male , Meningitis, Cryptococcal/immunology , Meningitis, Cryptococcal/microbiology , Middle Aged , Prospective Studies
10.
Antimicrob Agents Chemother ; 52(2): 735-8, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18070977

ABSTRACT

Synergistic interactions were observed between CIs and antifungal agents against 53 (90%) of 59 Cryptococcus neoformans isolates from solid organ transplant recipients with cryptococcosis and may account for better outcomes in patients with cryptococcosis receiving these immunosuppressive agents.


Subject(s)
Antifungal Agents/pharmacology , Calcineurin Inhibitors , Cryptococcosis/drug therapy , Cryptococcus neoformans/drug effects , Immunosuppressive Agents/pharmacology , Organ Transplantation/adverse effects , Tacrolimus/pharmacology , Antifungal Agents/therapeutic use , Cryptococcosis/microbiology , Drug Synergism , Humans , Immunosuppressive Agents/therapeutic use , Microbial Sensitivity Tests , Tacrolimus/therapeutic use , Treatment Outcome
11.
J Infect Dis ; 195(5): 756-64, 2007 Mar 01.
Article in English | MEDLINE | ID: mdl-17262720

ABSTRACT

Variables influencing the risk of dissemination and outcome of Cryptococcus neoformans infection were assessed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, international study. Sixty-one percent (68/111) of the patients had disseminated infection. The risk of disseminated cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR], 6.65; P=.048). The overall mortality rate at 90 days was 14% (16/111). The mortality rate was higher in patients with abnormal mental status (P=.023), renal failure at baseline (P=.028), fungemia (P=.006), and disseminated infection (P=.035) and was lower in those receiving a calcineurin-inhibitor agent (P=.003). In a multivariable analysis, the receipt of a calcineurin-inhibitor agent was independently associated with a lower mortality (adjusted HR, 0.21; P=.008), and renal failure at baseline with a higher mortality rate (adjusted HR, 3.14; P=.037). Thus, outcome in transplant recipients with cryptococcosis appears to be influenced by the type of immunosuppressive agent employed. Additionally, discerning the basis for transplant type-specific differences in disease severity has implications relevant for yielding further insights into the pathogenesis of C. neoformans infection in transplant recipients.


Subject(s)
Calcineurin Inhibitors , Cryptococcosis/microbiology , Cryptococcosis/mortality , Cryptococcus neoformans/drug effects , Immunosuppressive Agents/pharmacology , Organ Transplantation , Adult , Aged , Female , Humans , Male , Middle Aged , Treatment Outcome
12.
Med Mycol ; 44(5): 445-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16882611

ABSTRACT

We assessed predictive factors and characteristics of patients with late-onset invasive aspergillosis in the current era of novel immunosuppressive agents. Forty transplant recipients with invasive aspergillosis were included in this prospective, observational study initiated in 2003 at our institutions. In 50% (20/40) of these patients, the infections were late-occurring. Receipt of sirolimus in conjunction with tacrolimus for refractory rejection or cardiac allograft vasculopathy (P=0.047) was significantly associated with late-onset infection. The use of depleting or non-depleting T or B-cell antibodies, either as induction or as antirejection therapy did not correlate with time to onset of invasive aspergillosis. Mortality at 90 days was 20% (4/20) for the patients with early-onset infection and 45% (9/20) for those with late-onset infection (P=0.17). Thus, nearly one-half of the Aspergillus infections in transplant recipients in the current era are late-occurring. These data have implications relevant for prophylactic strategies and guiding clinical management of transplant recipients presenting with pulmonary infiltrates.


Subject(s)
Antifungal Agents/administration & dosage , Aspergillosis , Immunosuppressive Agents/administration & dosage , Organ Transplantation/adverse effects , Postoperative Complications , Sirolimus/administration & dosage , Tacrolimus/administration & dosage , Adult , Age of Onset , Aged , Antibodies/administration & dosage , Antibodies/immunology , Aspergillosis/epidemiology , Aspergillosis/etiology , Aspergillosis/prevention & control , B-Lymphocytes/immunology , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Prospective Studies , Risk Factors , Spain , T-Lymphocytes/immunology , Treatment Outcome , United States
13.
Adv Chronic Kidney Dis ; 13(3): 280-94, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16815233

ABSTRACT

Post-kidney transplant infection is the most common life-threatening complication of long-term immunosuppressive therapy. Optimal immunosuppression, in which a balance is maintained between prevention of rejection and avoidance of infection, is the most challenging aspect of posttransplantation care. The study of infectious complications in immunologically compromised recipients is changing rapidly, particularly in the fields of prophylactic and preemptive strategies, molecular diagnostic methods, and antimicrobial agents. In addition, emerging pathogens such as BK polyomavirus and West Nile flavivirus infections and the introduction of newer immunosuppressive agents that constantly change the risk profiles for opportunistic infections has added layers of complexity to this burgeoning field. Although remarkable progress has been made in these disciplines, comprehensive understanding of the clinical manifestations of infections remains limited, and the standardization of prophylaxis, diagnosis, and treatment of most infections is yet inadequately defined. The long-term goal for optimal care of transplant recipients, with respect to infection, is the prevention and/or early recognition and treatment of infections while avoiding drug-related toxicities.


Subject(s)
Bacterial Infections/etiology , Kidney Transplantation/adverse effects , Virus Diseases/etiology , Graft Rejection/prevention & control , Humans , Immunosuppression Therapy/adverse effects , Kidney Failure, Chronic/surgery , Risk Factors
14.
Transpl Immunol ; 16(2): 69-72, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16860707

ABSTRACT

BACKGROUND: The role of Th1 and Th2 mediated cytokine responses in the pathogenesis of Cryptococcus neoformans infection in organ transplant recipients has not been defined. METHODS: We assessed cytokine levels in the sera and CSF collected prospectively at the time of diagnosis of infection in 25 transplant recipients with cryptococcosis. Serum levels were compared with those in healthy individuals and transplant recipients without cryptococcosis. IFN-gamma or IL-12 (Th1)/IL-10 (Th2) ratio < 1.0 was considered a dominant Th2 response. RESULTS: Cases had lower ratios of IFN-gamma/IL-10 (p = 0.03) and IL-12/IL-10 (p = 0.03) compared to healthy individuals. Cytokine responses, however, did not differ significantly for cases vs. transplant controls. Cases with fungemia compared to those without fungemia tended to have higher serum IL-10 levels (p = 0.07) and lower IL-12/IL-10 ratios (p = 0.06). CSF ratios of IFN-gamma/IL-10 (p = 0.04) and IL-12/IL-10 (p = 0.04) were lower in cases with cryptococcal meningitis compared to those without meningitis; 80% (8/10) of the cases with cryptococcal meningitis vs. 0% (4/4) of those without meningitis had CSF IFN-gamma/IL-10 ratio of < 1.0 (p = 0.015). The levels of IL-10 (p = 0.04) and IFN-gamma (p = 0.04) in the CSF in cases with cryptococcal meningitis were significantly higher than those in their serum, respectively. CONCLUSIONS: High expression of Th2 phenotype in cryptococcal meningitis and in fungemia suggests that Th dysregulation may contribute to the pathogenesis of cryptococcosis in organ transplant recipients.


Subject(s)
Cryptococcus neoformans , Fungemia/immunology , Meningitis, Cryptococcal/immunology , Organ Transplantation , Th1 Cells/immunology , Th2 Cells/immunology , Cytokines/blood , Cytokines/cerebrospinal fluid , Cytokines/immunology , Female , Fungemia/blood , Fungemia/cerebrospinal fluid , Fungemia/pathology , Humans , Male , Meningitis, Cryptococcal/blood , Meningitis, Cryptococcal/cerebrospinal fluid , Meningitis, Cryptococcal/pathology , Organ Transplantation/adverse effects , Prospective Studies , Th1 Cells/pathology , Th2 Cells/pathology
15.
Transplantation ; 81(3): 320-6, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16477215

ABSTRACT

BACKGROUND: : The efficacy of the combination of voriconazole and caspofungin when used as primary therapy for invasive aspergillosis in organ transplant recipients has not been defined. METHODS: : Transplant recipients who received voriconazole and caspofungin (n=40) as primary therapy for invasive aspergillosis (proven or probable) in a prospective multicenter study between 2003 and 2005 were compared to a control group comprising a cohort of consecutive transplant recipients between 1999 and 2002 who had received a lipid formulation of AmB as primary therapy (n=47). In vitro antifungal testing of Aspergillus isolates to combination therapy was correlated with clinical outcome. RESULTS: : Survival at 90 days was 67.5% (27/40) in the cases, and 51% (24/47) in the control group (HR 0.58, 95% CI, 0.30-1.14, P=0.117). However, in transplant recipients with renal failure (adjusted HR 0.32, 95% CI: 0.12-0.85, P=0.022), and in those with A. fumigatus infection (adjusted HR 0.37, 95% CI: 0.16-0.84, P=0.019), combination therapy was independently associated with an improved 90-day survival in multivariate analysis. No correlation was found between in vitro antifungal interactions of the Aspergillus isolates to the combination of voriconazole and caspofungin and clinical outcome. CONCLUSIONS: : Combination of voriconazole and caspofungin might be considered preferable therapy for subsets of organ transplant recipients with invasive aspergillosis, such as those with renal failure or A. fumigatus infection.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Organ Transplantation/mortality , Peptides, Cyclic/therapeutic use , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Adult , Aged , Antifungal Agents/pharmacology , Aspergillosis/complications , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/isolation & purification , Caspofungin , Drug Therapy, Combination , Echinocandins , Female , Humans , Lipopeptides , Male , Middle Aged , Peptides, Cyclic/pharmacology , Pyrimidines/pharmacology , Renal Insufficiency/complications , Treatment Outcome , Triazoles/pharmacology , Voriconazole
16.
Transplantation ; 80(8): 1033-9, 2005 Oct 27.
Article in English | MEDLINE | ID: mdl-16278582

ABSTRACT

BACKGROUND: Therapeutic practices for Cryptococcus neoformans infection in transplant recipients vary, particularly with regards to antifungal agent employed, and duration of therapy. The risk of relapse and time to recurrence is not known. We assessed antifungal treatment practices for cryptococcosis in a cohort of prospectively followed organ transplant recipients. METHODS: The patients comprised 83 transplant recipients with cryptococcosis followed for a median of 2.1 and up to 5.2 years. RESULTS: Patients with central nervous system infection (69% vs. 16%, P = 0.00001), disseminated infection (82.7% vs. 20%, P = 0.00001), and fungemia (29% vs. 8%, P = 0.046) were more likely to receive regimens containing amphotericin B than fluconazole as primary therapy. The use of fluconazole, on the other hand, was more likely for infection limited to the lungs (64% vs. 14%, P = 0.00002). Survival at 6 months tended to be lower in patients whose CSF cultures at 2 weeks were positive compared to those whose CSF cultures were negative (50% vs. 91%, P = 0.06). Maintenance therapy was employed in 68% (54/79) of the patients who survived >3 weeks. The median duration of maintenance therapy was 183 days; 55% received maintenance for > or = 6 months and 25% for >1 year. Relapse was documented in 1.3% (1/79) of the patients. CONCLUSIONS: A majority of the organ transplant recipients with cryptococcosis receive maintenance antifungal therapy for 6 months with low risk of relapse. These data can assist in trials to assess the optimal therapeutic approach and duration of therapy for cryptococcosis in transplant recipients.


Subject(s)
Antifungal Agents/therapeutic use , Cryptococcosis/drug therapy , Opportunistic Infections/drug therapy , Organ Transplantation , Adult , Aged , Cryptococcus neoformans , Female , Humans , Male , Middle Aged , Treatment Outcome
17.
Clin Infect Dis ; 40(12): 1756-61, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15909263

ABSTRACT

BACKGROUND: We describe an immune reconstitution syndrome (IRS)-like entity in the course of evolution of Cryptococcus neoformans infection in organ transplant recipients. METHODS: The study population comprised a cohort of 83 consecutive organ transplant recipients with cryptococcosis who were observed for a median of 2 years in an international, multicenter study. RESULTS: In 4 (4.8%) of the 83 patients, an IRS-like entity was observed a median of 5.5 weeks after the initiation of appropriate antifungal therapy. Worsening of clinical manifestations was documented, despite cultures being negative for C. neoformans. These patients were significantly more likely to have received tacrolimus, mycophenolate mofetil, and prednisone as the regimen of immunosuppressive therapy than were all other patients (P = .007). The proposed basis of this phenomenon is reversal of a predominantly Th2 response at the onset of infection to a Th1 proinflammatory response as a result of receipt of effective antifungal therapy and a reduction in or cessation of immunosuppressive therapy. CONCLUSIONS: This study demonstrated that an IRS-like entity occurs in organ transplant recipients with C. neoformans infection. Furthermore, this entity may be misconstrued as a failure of therapy. Immunomodulatory agents may have a role as adjunctive therapy in such cases.


Subject(s)
Cryptococcosis/etiology , Immune System Diseases/etiology , Organ Transplantation/adverse effects , Adult , Aged , Antifungal Agents/therapeutic use , Cohort Studies , Cryptococcosis/drug therapy , Female , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Mycophenolic Acid/adverse effects , Mycophenolic Acid/analogs & derivatives , Prednisone/adverse effects , Tacrolimus/adverse effects
18.
Am J Transplant ; 4(10): 1720-4, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15367232

ABSTRACT

Immunosuppression for organ transplantation results in increased susceptibility to opportunistic infections including fungal, such as Scedosporium apiospermum. Even though many reported cases of this infection had both local and systemic manifestations, majority of the systemic infections had a fatal outcome. We report a case of a 50-year-old Caucasian male with lymphocutaneous and presumed pulmonary Scedosporium infection 4 years after renal transplantation that was successfully treated with voriconazole and discontinuation of immunosuppression. He received a second transplant 3 years later in the absence of clinical evidence of S. apiospermum infection. Unfortunately, 4 months after transplantation he developed recurrence of the same infection localizing to the soft tissues. Presently this infection is under control with surgical excision and voriconazole therapy. To our knowledge this is the first reported case of recurrent S. apiospermum infection in a renal transplant recipient. We suggest prophylactic antifungal therapy in all re-transplants with this infection.


Subject(s)
Kidney Transplantation , Mycetoma/physiopathology , Scedosporium , Humans , Immunosuppression Therapy/adverse effects , Lung/diagnostic imaging , Male , Middle Aged , Recurrence , Skin/microbiology , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...